cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bioatla Inc
5 own
4 watching
Current Price
$4
$0.21
(5.54%)
logo-bcab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
150.31M
52-Week High
52-Week High
12.15
52-Week Low
52-Week Low
2.01
Average Volume
Average Volume
0.56M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization150.31M
icon52-Week High12.15
icon52-Week Low2.01
iconAverage Volume0.56M
iconDividend Yield--
iconP/E Ratio--
What does the Bioatla Inc do?
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Read More
How much money does Bioatla Inc make?
News & Events about Bioatla Inc.
Globe Newswire
23days ago
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) Phase 2 part 2 of the potentially registrational study is...
Globe Newswire
1month ago
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Companys management will ...
PR Newswire
2 months ago
Himalaya Therapeutics Announces Highlights of Recent Clinical Progress Himalaya Therapeutics Announces Highlights of Recent Clinical Progress PR Newswire SAN DIEGO and SHANGHAI, Nov. 8, 2022 Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with...
Globe Newswire
2 months ago
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Scott Smith, President and Sheri ...
Globe Newswire
3 months ago
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has agreed to sell 9,745,128 ...
Frequently Asked Questions
Frequently Asked Questions
What is Bioatla Inc share price today?
plus_minus_icon
Can Indians buy Bioatla Inc shares?
plus_minus_icon
How can I buy Bioatla Inc shares from India?
plus_minus_icon
Can Fractional shares of Bioatla Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Bioatla Inc stocks?
plus_minus_icon
What is today’s traded volume of Bioatla Inc?
plus_minus_icon
What is today’s market capitalisation of Bioatla Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Bioatla Inc?
plus_minus_icon
What percentage is Bioatla Inc down from its 52-Week High?
plus_minus_icon
What percentage is Bioatla Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4
$0.21
(5.54%)
logo-bcab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00